Niraparib, marketed as Zejula, is an oral poly(ADP-ribose) polymerase (PARP) inhibitor used in the treatment of ovarian cancer [1]. It works by blocking the activity of PARP enzymes, which play a role in DNA repair [2]. When these enzymes are blocked, cancer cells with existing DNA repair defects, such as those with BRCA mutations, are unable to repair their damaged DNA and die [2].
What types of ovarian cancer is Zejula approved for?
Zejula is approved for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy [3]. It is also approved for the maintenance treatment of adult patients with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy [3].
How does Zejula compare to other PARP inhibitors?
Niraparib (Zejula) belongs to a class of drugs called PARP inhibitors, which includes other medications like olaparib (Lynparza), rucaparib (Rubraca), and talazoparib (Talzenna) [4]. While they all target PARP enzymes, they may differ in their specific indications, efficacy in different patient populations, and side effect profiles [4]. For instance, niraparib is approved for both BRCA-mutated and non-BRCA-mutated advanced ovarian cancer patients as maintenance therapy, whereas other PARP inhibitors might have more specific indications related to germline or somatic BRCA mutations [3][4].
What are the most common side effects of Zejula?
The most common side effects reported with Zejula include bone marrow suppression, such as anemia, thrombocytopenia, and neutropenia, as well as gastrointestinal issues like nausea and vomiting, fatigue, and hypertension [1][5]. Patients are monitored for these side effects, and dosage adjustments or temporary discontinuation of treatment may be necessary [5].
When does the patent for Zejula expire?
Patent exclusivity for pharmaceutical drugs is a complex area. For Zejula (niraparib), information on specific patent expiry dates can be found through resources that track drug patents and intellectual property. DrugPatentWatch.com is a source that provides detailed patent information for pharmaceuticals [6]. These patents typically cover the composition of matter, methods of use, and manufacturing processes, and their expiry dates determine when generic versions may become available [6].
Can generic versions of Zejula be developed?
The development of generic versions of Zejula is contingent upon the expiration of relevant patents and any other market exclusivities granted by regulatory bodies [6]. Once these protections lapse, other manufacturers can seek approval to market generic niraparib products, potentially increasing market competition and lowering costs [6].
What clinical trials have been conducted for Zejula?
Zejula has been evaluated in several key clinical trials. The NOVA trial demonstrated its efficacy as a monotherapy maintenance treatment in patients with newly diagnosed or recurrent ovarian cancer, showing a significant improvement in progression-free survival in both BRCA-mutated and non-BRCA-mutated populations [7]. Other trials have explored its use in combination with other therapies and in different lines of treatment [7].
What regulatory approvals does Zejula have?
Zejula has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses in ovarian cancer treatment [3][8]. These approvals are based on the review of clinical trial data demonstrating the drug's safety and efficacy.
What are patient concerns regarding Zejula?
Patients often have concerns regarding the potential side effects of Zejula, particularly hematological toxicities like low blood counts and the risk of hypertension [5]. Understanding the management of these side effects, as well as the expected duration of treatment and its impact on quality of life, are common patient queries [5].
How is Zejula administered?
Zejula is taken orally, typically once daily, as a capsule [1]. The dosage and duration of treatment are determined by the prescribing physician based on the patient's diagnosis, response to therapy, and tolerance of the drug [5].
Sources:
[1] https://www.drugs.com/zezulta.html
[2] https://www.cancer.gov/about-cancer/treatment/types/chemotherapy/parp-inhibitors-fact-sheet
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-orphan-drug-designations
[4] https://www.cancer.net/navigating-cancer-care/treatment/targeted-therapies/parp-inhibitors
[5] https://www.rxlist.com/zezulta-side-effects-drug-center.htm
[6] https://drugpatentwatch.com/
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa1610155
[8] https://www.ema.europa.eu/en/medicines/human/EPAR/zezulta